BioVie Inc.Long
BIVI - speculative catalyst play
BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Disclaimer: This is not financial advice.
Anticipated Phase 2 Data Release Date: 04/24/2024
This represents a highly speculative investment opportunity with a favorable risk/reward ratio.
Stop Loss (SL): Set below $0.43 to limit potential losses.
Take Profit (TP): Target around $0.87, with potential for higher gains.
Refer to the accompanying chart for detailed information.
Please trade with caution.
Disclaimer: This is not financial advice.
Anticipated Phase 2 Data Release Date: 04/24/2024
This represents a highly speculative investment opportunity with a favorable risk/reward ratio.
Stop Loss (SL): Set below $0.43 to limit potential losses.
Take Profit (TP): Target around $0.87, with potential for higher gains.
Refer to the accompanying chart for detailed information.
Please trade with caution.
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.